{"entity":{"id":"nct06119685","kind":"trial","name":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","aka":[],"tldr":"A phase 1/2 trial of Rituximab, Daratumumab, Aldesleukin in multiple myeloma and hodgkin lymphoma, run by Indapta Therapeutics, INC., now recruiting.","summary":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers is a phase 1/2 interventional study registered as NCT06119685 by Indapta Therapeutics, INC., with 128 participants planned, started 2023-10-25 and due to reach its primary completion in 2025-12-30. Interventions recorded: IDP-023, Rituximab, Daratumumab, Interleukin-2, Cyclophosphamide. Conditions listed: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06119685","url":"https://clinicaltrials.gov/study/NCT06119685"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["rituximab","daratumumab","aldesleukin","cyclophosphamide","fludarabine","mesna"],"companies":["indapta-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06119685","phase":"1/2","setting":"Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","sponsor":"Indapta Therapeutics, INC.","enrolled":128,"outcomes":[]},"route":"/trials/nct06119685/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"},{"id":"mesna","kind":"drug","name":"Mesna","route":"/drugs/mesna/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"indapta-therapeutics","kind":"company","name":"Indapta Therapeutics","route":"/companies/indapta-therapeutics/"}]}}